Trial Profile

A Phase 1/2 Study of TPX-0046, A Novel Oral RET/SRC Inhibitor in Adult Subjects With Advanced/Metastatic Solid Tumors Harboring Oncogenic RET Fusions or Mutations

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 17 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Enbezotinib (Primary)
Indications Medullary thyroid cancer; Non-small cell lung cancer; Solid tumours; Thyroid cancer
Focus Adverse reactions; First in man; Therapeutic Use
Acronyms SWORD-1
Sponsors Turning Point Therapeutics

Most Recent Events

14 Jun 2023 Status changed from active, no longer recruiting to discontinued (due to Adverse change in the risk/benefit).
09 Feb 2023 Planned End Date changed from 1 Nov 2026 to 1 Nov 2023.
09 Feb 2023 Planned primary completion date changed from 1 Dec 2025 to 1 Jul 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com